Samuel Z. Goldhaber, MD; Michael Berkwits, MD, MSCE, Deputy Editor
Potential Financial Conflicts of Interest: Consultancies: S.Z. Goldhaber (Sanofi-Aventis, GlaxoSmithKline, Emisphere, Bayer, Boehringer Ingelheim); Grants received: S.Z. Goldhaber (Sanofi-Aventis, Eisai, GlaxoSmithKline).
Requests for Single Reprints: Samuel Z. Goldhaber, MD, Brigham & Women's Hospital, 75 Francis Street, Boston, MA 02115.
Current Author Addresses: Dr. Goldhaber: Brigham & Women's Hospital, 75 Francis Street, Boston, MA 02115.
Dr. Berkwits: American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106.
Goldhaber SZ, Berkwits M. Trials That Matter: Can Patients with Venous Thromboembolism Be Treated with Fixed-Dose Subcutaneous Unfractionated Heparin?. Ann Intern Med. 2006;145:929-931. doi: 10.7326/0003-4819-145-12-200612190-00011
Download citation file:
Published: Ann Intern Med. 2006;145(12):929-931.
Unfractionated heparin (UFH) was the mainstay of initial treatment for acute venous thromboembolism (VTE) until low-molecular-weight heparin (LMWH) became available in the 1990s. Low-molecular-weight heparin was an attractive alternative to UFH because its excellent bioavailability allowed for convenient fixed, weight-based dosing. High-quality research subsequently confirmed the superior efficacy, safety, and cost-effectiveness of LMWH over UFH for treatment of deep venous thrombosis (1-4). As a result, most patients with this disorder who would require a minimum 5-day hospitalization if treated with UFH can now be treated with LMWH in an overnight stay or in the outpatient setting. Some evidence even supports the use of LMWH for less severe forms of pulmonary embolism (5).
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only